You are here

Article Text

Article menu
Download PDFPDF
ORIGINAL ARTICLE
Relationship between p53-associated proteins and estrogen receptor status in ovarian serous neoplasms
  1. E. Y. Cho*,
  2. Y. L. Choi*,
  3. S. W. Chae†,
  4. J. H. Sohn† and
  5. G. H. Ahn*
  1. * Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  2. † Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
  1. Address correspondence and reprint request to: Geung Hwan Ahn, MD, PhD, Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-Dong, Kangnam-gu, Seoul 135-710, Korea. Email: gahn{at}smc.samsung.co.kr

Abstract

We studied the immunoexpression of p14ARF, MDM2, and p53, in addition to relationships between those protein expressions and estrogen receptor (ER)α in ovarian serous tumors including benign (n = 23), borderline (n = 41), and malignant (n = 94). The aberrant expressions of p14ARF, MDM2, and p53 were observed in 19.6% (31/158), 47.5% (75/158), and 39.9% (63/158) of cases, respectively. The expression of MDM2 was significantly higher in borderline tumors compared to benign (P = 0.04) and malignant (P < 0.01) tumors. p53 expression in borderline tumors was uncommon, and p14ARF expression loss was mainly observed in carcinomas. Altered expression of p14ARF, MDM2, and p53 shows significant relationship with stage. Overexpression of MDM2 (P = 0.01) and loss of p14ARF expression (P = 0.04) were significantly associated with ER expression. Our results suggest that alteration of p14ARF–MDM2–p53 pathway proteins may contribute significantly to the tumorigenesis of ovarian serous neoplasms, and ER is involved in cellular regulation of p14ARF–MDM2–p53 pathway in ovarian serous neoplasms.

  • ER
  • ovarian serous neoplasms
  • p14ARF–MDM2–p53 pathway

https://doi.org/10.1136/ijgc-00009577-200605000-00008

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.